Format

Send to

Choose Destination
Biomark Med. 2014;8(10):1207-17. doi: 10.2217/bmm.14.90.

The identification of three novel biomarkers of major adverse kidney events.

Author information

1
Department of Nephrology & Hypertension, Diabetes & Endocrinology Otto-von-Guericke University, Magdeburg, Germany.

Abstract

AIM:

To describe the prognostic value of three novel biomarkers for acute adverse kidney events compared with routine biological markers.

MATERIAL & METHODS:

We used high-end MS to quantify biomarkers predictive of acute kidney injury (AKI) and major adverse kidney events (MAKE) in 100 adult patients after open heart surgery (n = 100).

RESULTS:

Early postoperatively measured LG3 (a C-terminal fragment of perlecan), LTBP2 (latent transforming growth factor binding protein-2), Cathepsin L as well as two other renal biomarkers (NGAL, Cystatin C) had greater predictive value for AKI (n = 23) and MAKE (n = 24) compared with creatinine, urea and urine output.

CONCLUSIONS:

LG3, LTBP2 and Cathepsin L deserve further exploration as biomarkers for the early identification of patients at risk of MAKE.

KEYWORDS:

C-terminal fragment of perlecan; LG3; LTBP2; MAKE; NGAL; cathepsin L; creatinine; cystatin C; latent transforming growth factor binding protein-2; major adverse kidney event; neutrophil gelatinase-associated lipocalin; urea; urine output

PMID:
25525981
DOI:
10.2217/bmm.14.90
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center